Brief: Hls Therapeutics Reports Efficacy And Safety Results From Pilot Study Treating Covid-19 Infected Outpatients With Vascepa®

HLS Therapeutics

14/12/2020 11:33

Dec 14 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS REPORTS EFFICACY AND SAFETY RESULTS FROM
PILOT
STUDY TREATING COVID-19 INFECTED OUTPATIENTS WITH VASCEPA®
(ICOSAPENT ETHYL)
    * HLS THERAPEUTICS INC - VASCEPA COVID-19 CARDIOLINK-9
RANDOMIZED
TRIAL SUGGESTS IMPROVEMENT IN PATIENT-REPORTED COVID-19 SYMPTOMS
    * HLS THERAPEUTICS - VASCEPA ADMINISTRATION RESULTED IN
SIGNIFICANT 52% REDUCTION OF TOTAL PATIENT-REPORTED SYMPTOM
OUTCOME PREVALENCE SCORE
    * HLS THERAPEUTICS - LARGER FOLLOW-ON CLINICAL STUDIES
COMMENCED
OF VASCEPA AS THERAPEUTIC OPTION IN COVID-19 SETTINGS,
ANTICIPATED TO BE COMPLETED IN 2021

Source text for Eikon:  ID:nCNWTphfza 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))